Close
x
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX Nov 30 2021 12:00
    57,064.87 -195.71 (-0.34%)
  • NIFTY Nov 30 2021 12:00
    16,983.20 -70.75 (-0.41%)
  • SENSEX Nov 30 2021 12:00
    57,064.87 -195.71 (-0.34%)
  • NIFTY Nov 30 2021 12:00
    16,983.20 -70.75 (-0.41%)
  • Nasdaq Nov 30 2021 04:30
    15,782.83 +291.17 ( +1.88%)
  • DJIA Nov 30 2021 04:30
    35,135.94 +236.60 ( +0.68%)
  • S&P 500 Nov 30 2021 04:30
    4,655.27 +60.65 ( +1.32%)
  • Hang Seng Nov 30 2021 02:10
    23,475.26 -376.98 (-1.58%)
  • Crude Oil Nov 30 2021 11:22
    4,963.00 -380.00 (-7.11%)
  • Gold Nov 30 2021 11:14
    47,600.00 +13.00 ( +0.03%)
  • Silver Nov 30 2021 11:04
    61,670.00 +30.00 ( +0.05%)
  • Copper Nov 30 2021 11:22
    724.15 -10.65 (-1.45%)
  • Pound / Rupee Dec 23 2016 22:30
    99.73 +0.54 ( +0.54%)
  • Dollar / Rupee Dec 23 2016 22:30
    74.83 +0.41 ( +0.55%)
  • Euro / Rupee Dec 23 2016 22:30
    84.59 +1.15 ( +1.37%)
  • Yen / Rupee Dec 23 2016 22:30
    0.66 +0.01 ( +2.25%)

Divis Laboratories Ltd

BSE Code : 532488 | NSE Symbol : DIVISLAB | ISIN:INE361B01024| SECTOR : Pharmaceuticals |

NSE BSE
 
SMC down arrow

4,880.70

-49.50 (-1.00%) Volume 280564

30-Nov-2021 EOD

Prev. Close

4,930.20

Open Price

4,905.00

Bid Price (QTY)

0.00(0)

Offer Price (QTY)

0.00(0)

 

Today’s High/Low 4,950.00 - 4,841.00

52 wk High/Low 5,425.00 - 3,154.50

Key Stats

MARKET CAP (RS CR) 129567.25
P/E 61.48
BOOK VALUE (RS) 372.8905965
DIV (%) 1000
MARKET LOT 1
EPS (TTM) 79.39
PRICE/BOOK 13.08882563897
DIV YIELD.(%) 0.41
FACE VALUE (RS) 2
DELIVERABLES (%) 30.16
4

News & Announcements

08-Nov-2021

Divis Laboratories Ltd Slips 7.72%, S&P BSE Healthcare index Shed 1.43%

08-Nov-2021

IndusInd Bank Ltd leads losers in 'A' group

08-Nov-2021

Divis Laboratories Ltd - Divis Laboratories Limited - Outcome of Board Meeting

06-Nov-2021

Divi's Laboratories consolidated net profit rises 16.72% in the September 2021 quarter

29-Oct-2021

Divis Laboratories announces board meeting date

31-Jul-2021

Divis Laboratories to convene board meeting

20-Jul-2021

Divis Laboratories to conduct AGM

29-May-2021

Board of Divis Laboratories recommends final dividend

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Aarey Drugs & Pharmaceuticals Ltd 524412 AAREYDRUGS
Aarti Drugs Ltd 524348 AARTIDRUGS
Add Life Pharma Ltd 524665
Adithya Alkaloids Pvt Ltd 524320
Alpha Drug India Ltd(merged) 500006 ALPHADRUG
Ami Organics Ltd 543349 AMIORG
Anuh Pharma Ltd 506260
Anus Laboratories Ltd 532981
Arch Pharmalabs Ltd 524729
Aster Drugs & Pharmaceuticals Ltd 40286
Auro Laboratories Ltd 530233
Auromed Ltd 532103
Bacil Pharma Ltd 524516
Beta Drugs Ltd 535022 BETA
Betalact Laboratories Ltd 531238
Biotech Synergy Ltd 40183
Cheminor Drugs Ltd (Merged) 524140 CHEMNODRUG
Chemo Pharma Laboratories Ltd 506365
Chemox Chemical Industries Ltd (Wound-up) 512042 CHEMOXCHEM
Chiplun Fine Chemicals Ltd 530417
Core Laboratories Ltd (Merged) 506963
Coromandel Pharmaceuticals Ltd 524524
Daurala Organics Ltd(merged) 524256 DAURALAORG
Denis Chem Lab Ltd 537536
Dishman Pharmaceuticals and Chemicals Ltd(Merged) 532526 DISHMAN
Dynachem Pharmaceuticals (Export) Ltd 524562 DYNAPHARMA
Elder Pharmaceuticals Ltd 532322 ELDERPHARM
Elegant Pharmaceuticals Ltd 524344
Emergy Phaarma Ltd 524812
Everest Organics Ltd 524790
Fermenta Biotech Ltd 506414
Fernhill Industries Ltd 531466
Fine Drugs And Chemicals Ltd (Merged) 524782
Gennex Laboratories Ltd 531739
Gland Pharma Ltd 543245 GLAND
Godavari Drugs Ltd 530317
Granules India Ltd 532482 GRANULES
Gujarat Lyka Organics Ltd (Merged) 506930
Gujarat Themis Biosyn Ltd 506879 GUJTHEMIS
Hallmark Drugs & Chemicals Ltd 531407
Harshita Ltd 531347
Hikal Ltd 524735 HIKAL
Hiran Orgochem Ltd 506170
Hi-Tech Drugs Ltd 524424
Ishita Drugs & Industries Ltd 524400
J K Pharmachem Ltd 500218 JKPHARMA
Janak Intermediates Ltd 524380
Jubilant Pharmova Ltd 530019 JUBLPHARMA
Kaprinas Pharmaceuticals & Chemicals Ltd 530147
Kimia Biosciences Ltd 530313
Konar Organics Ltd 526933
Krebs Biochemicals & Industries Ltd 524518 KREBSBIO
Kwality Pharmaceuticals Ltd 539997
Lactose (India) Ltd 524202
Larite Industries Ltd 512325
Lupin Ltd 500257 LUPIN
Magnum Intermediates Ltd 40177
Manav Pharma Ltd 524390
Marksans Pharma Ltd 524404 MARKSANS
Medicorp Technologies India Ltd (Merged) 532108 MEDICOTECH
Nagarjuna Drugs Ltd 530064
Nagarjuna Nature Base Ltd 40353
Nalin Chemicals Ltd 531292
Natco Laboratories Ltd (Merged) 500299 NATCOLABS
Nectar Lifescience Ltd 532649 NECLIFE
Neuland Laboratories Ltd 524558 NEULANDLAB
NGL Fine Chem Ltd 524774
Nutraplus India Ltd 524764
Orchid Pharma Ltd 524372 ORCHPHARMA
Paam Drugs & Pharmaceuticals Ltd 524462 PAAMDRUG
Pan India Drugs & Chemicals Ltd 524560
Panchsheel Organics Ltd 531726 PANCHSHEEL
Par Drugs & Chemicals Ltd 535341 PAR
Parabolic Drugs Ltd 533211 PARABDRUGS
Parmax Pharma Ltd 540359
Pharmed Chemicals Ltd 524733
Piramal Phytocare Ltd(Merged) 532979 PIRPHYTO
Plama Laboratories Ltd (Merged) 524798
Pradeep Drug Company Ltd (Merged) 524246
Ratna Drugs Ltd 524382
Regent Chemicals Ltd 506989
Richline Pharma Ltd 524460
Roopa Industries Ltd 530991
Rupal Chemical Industries Ltd (Merged) 524705
Rupangi Impex Ltd (Wound-up) 512606 RUPANGIMPX
S S Organics Ltd 524636
Samrat Pharmachem Ltd 530125
Sequent Scientific Ltd 512529 SEQUENT
Sharvani Pharmaceuticals Ltd 40159
Shasun Pharmaceuticals Ltd(Merged) 524552 SHASUNPHAR
Shilpa Medicare Ltd 530549 SHILPAMED
Shilpax Laboratories Ltd 524482
Shrishma Fine Chemicals (Karnataka) Ltd 507000
Siris Ltd 524746 SIRIS
Smruthi Organics Ltd 540686
SMS Pharmaceuticals Ltd 532815 SMSPHARMA
Southern Herbals Ltd 500395 SOUTHNHERB
Sri Chakra Remedies Ltd (Merged) 507484
Stellar Drugs Ltd 524612
Sterling Basic Organics Ltd 524644
Suven Life Sciences Ltd 530239 SUVEN
Swet-Chem Antibiotics Ltd 531186
Targof Pure Drugs Ltd 40230
Teem Laboratories Ltd 507761
Transchem Ltd 500422 TRANSCHEM
Umedix India Ltd 524822
Venkat Pharma Ltd 532093
Venmax Drugs & Pharmaceuticals Ltd 531015
Vera Laboratories Ltd (Merged) 40228
Vitara Chemicals Ltd 524646 VITARACHEM
Vivo Bio Tech Ltd 511509
Vorin Laboratories Ltd (Merged) 524508
Wanbury Ltd 524212 WANBURY
Zora Pharma Ltd(merged) 524438
Zyden Gentec Ltd 530091

Share Holding

Category No. of shares Percentage
Total Foreign 55962409 21.08
Total Institutions 43418056 16.36
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 3686841 1.39
Total Promoters 137899200 51.95
Total Public & others 24503666 9.23
Total 265468580 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About Divi's Laboratories Ltd

Divi's Laboratories Ltd is an India based manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates. The company is engaged in manufacture of leading generic compounds, Nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies. Divis is among the largest pharmaceutical companies in India with a portfolio of 120 products across diverse therapeutic areas. The company has four manufacturing facilities and market presence across several countries. The first facility is located at village Lingojigudem in Yadadri Bhuvanagiri District near Hyderabad (Telangana) comprises 11 multipurpose production blocks with finished product areas for APIs. The second manufacturing unit is an export oriented unit located at village Chippada, Bheemunipatnam Mandal, about 30 KM from the port city of Visakhapatnam (Andhra Pradesh) on the east coast situated on a 100-acre site. The third facility is located at village Chippda situated on a sprawling 267-acre site and is a Special Economic Zone (SEZ) Unit in Pharma Sector. The fourth facility is located at the company's Pharma SEZ at village Chippada. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale process and structural confirmation. Divi's Laboratories Ltd was established in the year 1990 as Divis Research Center (DRC) with Research & Development as their prime fundamental. During the year 1991-93, the company successfully developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. In the year 1994, they changed their name to Divis Laboratories Ltd to reflect their growing area of operations. In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems. In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened 'DRC-Vizag' for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange. In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II. In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006. During the year 2006-07, the company developed an SEZ titled 'Divi's Pharma SEZ' on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1, 2008. During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called 'DSN SEZ Unit' at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011. During the year 2012-13, the company added 9 products to its product portfolio of which 3 are generic APIs and intermediates and 6 are custom synthesis APIs and intermediates. In 2014, the Korean Food and Drug Administration (KFDA) carried out inspection of the company's Visakhapatnam Unit-2 for the third time. During the year, fourth US FDA inspection was carried out at the company's Visakhapatnam Unit-2. Also during the year, fifth US FDA inspection was carried out for Unit-1. During the year, COFEPRIS (Mexico) inspected the company's Visakhapatnam Unit-2 for the first time. COFEPRIS (Mexico) also inspected the company's Choutuppal Unit-1 in Telangana for the first time in the year 2014. On 19 February 2016, Divi's Laboratories announced that it has had a successful inspection by the US-FDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February 2016 with no observations. The Board of Directors of Divi's Laboratories at its meeting held on 12 August 2016 approved and ratified one-time ex-gratia of an aggregate amount of Rs 79 crore to the employees and whole-time directors of the company on the occasion of completion of 25 years of formation of the company. On 8 April 2017, Divi's Laboratories announced that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from import alert issued under clauses 66-40 and 99-32 of the FDA regulations. On 22 April 2017, Divi's Laboratories announced that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam. On 4 August 2017, Divi's Laboratories announced that the inspection of the Unit-2 Visakhapatnam was completed successfully by HPRA (Ireland) and JAZMP (Slovenia). The inspection was focused on follow up on the effectiveness of the CAPA implemented from the last JAZMP inspection and general GMP inspection of the site. On 15 November 2017, Divi's Laboratories announced that the US-FDA has lifted/removed import alert 66-40 imposed on the company's Unit-II at Visakhapatnam. On 18 November 2017, Divi's Laboratories announced that the company has received an Establishment Inspection Report (EIR) from US-FDA for Unit-II at Visakhapatnam, as closure of audit by FDA. Earlier, the company had informed the stock exchanged that its Unit-II at Visakhapatnam was inspected by US-FDA in September 2017 wherein a Form-483 was issued with 6 observations. On 16 May 2018, Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations. As on 31 March 2018, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. During the year 2017-18, the company is making capacity additions at the existing manufacturing facilities and in this process we are building 2 additional production blocks at Unit-1 at Choutuppal. Capital WIP as at the year-end amounted to Rs 11976 lakhs. Capital expenditure incurred at the existing Units is to enhance capacities as well as upgrading utilities and infrastructure for compliances. As the company has significant accumulation of cash reserves, all capex has been funded with internal accruals. In order to cater to the increasing opportunities in generic and big pharma business, the Company during the FY2019, is taking up following two brownfield projects with an aggregate investment of Rs 1200 crore.a. An SEZ Unit at our Unit-II at Visakhapatnam, named as DCV SEZ Unit, with an investment of Rs 600 crore. (revised from the estimate of Rs 400 crore announced at the last General Meeting),b. Another SEZ Project with an investment of Rs 600 crore in the available land at our Unit-I in Bhuvangiri-Yadadri (erstwhile Nalgonda) District, Telangana State. The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March 2020. The Company has also taken up debottlenecking programs at Unit-I as well as Unit-II by investing an aggregate amount of Rs 300 crore -which would also create additional capacities for existing products. In addition, the company also taken up augmentation of waste treatment infrastructure at Unit-II at an estimated cost of Rs 150 crore. A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21. The balance works of the brownfield projects of DC-SEZ and DCVSEZ are also expected to be completed by second half of financial year 2020-21. As on 31 March 2020, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. Eventhough there was a nationwide lockdown restrictions due to COVID-19 pandemic since March 24, 2020, the Government has exempted manufacturing units of essential goods including drugs and pharmaceuticals, medical devices, their raw materials and intermediates from the lockdown restrictions, amongst others. The Company has been operating in compliance with the various advisories/ guidelines passed by the Government of India, State Governments and statutory institutions. The new brownfield DC and DCV SEZ Units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the FY2021. Also Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. During the year 2020-21, the company also taken up another capex program with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project. A part of the project has been completed and became operational and the rest of the capex will be completed during early part of the next financial year i.e.2021-22.

Divi's Laboratories Ltd Chairman Speech

Dear Shareholders,

The year 2020-21 has seen the emergence of a health crisis caused by the Covid-19 pandemic and has been immensely challenging for each one of us. The loss of lives and livelihoods has left a lasting pain, which is sure to leave an indelible mark on us. My heart goes out to everyone out there who has su_ered the loss of their loved one.

In responding to these challenges, we were guided by our core principles and we remained true to our purpose of maintaining sustainable operations. Being at the forefront of the pharmaceutical industry, Divi's as a company in its capacity has been contributing to fight the pandemic since Day 1 and we continue to do our part in helping communities around our manufacturing units.

Over the course of the past 30 years, your Company has kept its focus on the principle of ‘Sustained Growth' making sure that the leaps we take, contribute positively to the continued rigor of our operations. Our long-term plan is founded on this purpose of maintaining sustainability, which has helped us scale our operations over time. This has improved our overall reach and has generated greater value for our brand, as we now head into a new decade as one of the leaders in this industry.

The Year in Perspective – A bird's eye view

On the business front, your Company has shown incredible resilience and momentum in response to the Covid-19 pandemic. It has been a year of challenges and uncertainty and we are proud of the relentless commitment and dedication of the entire Divi's family. Our agility, adaptability, resilience and responsiveness to our customer needs, earned us tremendous goodwill and has enhanced our standing in the market. We faced operational challenges due to restricted movement and disrupted supply lines during the first few months of the pandemic, in 2020. As the second wave of the pandemic unfolded with predictions of a third wave in the near future, our focus continues to be on our people's health and safety, ensuring uninterrupted supplies of APIs to our customers.

Our business performance in the year is also a reflection of the innate adaptability within the company. The early months of the pandemic brought disruption and uncertainty to our business and to all our customers, colleagues, suppliers and shareholders. When the worldwide lockdown disturbed economic activity across virtually all sectors, Divi's responded with speed and agility, embracing a new operating model due to the kind of expansion programmes we undertook over the years. Despite the intensity of the second wave of Covid-19, we believe that we are in a far better place as we complete FY2021.

The Road Ahead - Purpose, People, Planet

We are entering FY2022 powered by strong sustainable strategies and are more determined to keep formulating robust strategies and means to combat the challenges thrown at us by the pandemic. Our focus remains steadfast on operating our assets and facilities at full capacity, putting in place our expansion plans and keeping the safety of our employees at the forefront.

I take immense pride in the way our employees have demonstrated strength, conviction and courage during these difficult times and I am indebted to each one of them for having stood solidly behind the company.Mostimportantly,Iwould like to thank our shareholders, for the overwhelming trust, support, and confidence in Divi's. Our commitment to being a reliable supplier, delivering quality APIs - remains unchanged.

Regards,
Dr. Murali K. Divi
Managing Director

   

Divi's Laboratories Ltd Company History

Divi's Laboratories Ltd is an India based manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates. The company is engaged in manufacture of leading generic compounds, Nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies. Divis is among the largest pharmaceutical companies in India with a portfolio of 120 products across diverse therapeutic areas. The company has four manufacturing facilities and market presence across several countries. The first facility is located at village Lingojigudem in Yadadri Bhuvanagiri District near Hyderabad (Telangana) comprises 11 multipurpose production blocks with finished product areas for APIs. The second manufacturing unit is an export oriented unit located at village Chippada, Bheemunipatnam Mandal, about 30 KM from the port city of Visakhapatnam (Andhra Pradesh) on the east coast situated on a 100-acre site. The third facility is located at village Chippda situated on a sprawling 267-acre site and is a Special Economic Zone (SEZ) Unit in Pharma Sector. The fourth facility is located at the company's Pharma SEZ at village Chippada. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale process and structural confirmation. Divi's Laboratories Ltd was established in the year 1990 as Divis Research Center (DRC) with Research & Development as their prime fundamental. During the year 1991-93, the company successfully developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. In the year 1994, they changed their name to Divis Laboratories Ltd to reflect their growing area of operations. In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems. In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened 'DRC-Vizag' for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange. In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II. In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006. During the year 2006-07, the company developed an SEZ titled 'Divi's Pharma SEZ' on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1, 2008. During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called 'DSN SEZ Unit' at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011. During the year 2012-13, the company added 9 products to its product portfolio of which 3 are generic APIs and intermediates and 6 are custom synthesis APIs and intermediates. In 2014, the Korean Food and Drug Administration (KFDA) carried out inspection of the company's Visakhapatnam Unit-2 for the third time. During the year, fourth US FDA inspection was carried out at the company's Visakhapatnam Unit-2. Also during the year, fifth US FDA inspection was carried out for Unit-1. During the year, COFEPRIS (Mexico) inspected the company's Visakhapatnam Unit-2 for the first time. COFEPRIS (Mexico) also inspected the company's Choutuppal Unit-1 in Telangana for the first time in the year 2014. On 19 February 2016, Divi's Laboratories announced that it has had a successful inspection by the US-FDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February 2016 with no observations. The Board of Directors of Divi's Laboratories at its meeting held on 12 August 2016 approved and ratified one-time ex-gratia of an aggregate amount of Rs 79 crore to the employees and whole-time directors of the company on the occasion of completion of 25 years of formation of the company. On 8 April 2017, Divi's Laboratories announced that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from import alert issued under clauses 66-40 and 99-32 of the FDA regulations. On 22 April 2017, Divi's Laboratories announced that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam. On 4 August 2017, Divi's Laboratories announced that the inspection of the Unit-2 Visakhapatnam was completed successfully by HPRA (Ireland) and JAZMP (Slovenia). The inspection was focused on follow up on the effectiveness of the CAPA implemented from the last JAZMP inspection and general GMP inspection of the site. On 15 November 2017, Divi's Laboratories announced that the US-FDA has lifted/removed import alert 66-40 imposed on the company's Unit-II at Visakhapatnam. On 18 November 2017, Divi's Laboratories announced that the company has received an Establishment Inspection Report (EIR) from US-FDA for Unit-II at Visakhapatnam, as closure of audit by FDA. Earlier, the company had informed the stock exchanged that its Unit-II at Visakhapatnam was inspected by US-FDA in September 2017 wherein a Form-483 was issued with 6 observations. On 16 May 2018, Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations. As on 31 March 2018, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. During the year 2017-18, the company is making capacity additions at the existing manufacturing facilities and in this process we are building 2 additional production blocks at Unit-1 at Choutuppal. Capital WIP as at the year-end amounted to Rs 11976 lakhs. Capital expenditure incurred at the existing Units is to enhance capacities as well as upgrading utilities and infrastructure for compliances. As the company has significant accumulation of cash reserves, all capex has been funded with internal accruals. In order to cater to the increasing opportunities in generic and big pharma business, the Company during the FY2019, is taking up following two brownfield projects with an aggregate investment of Rs 1200 crore.a. An SEZ Unit at our Unit-II at Visakhapatnam, named as DCV SEZ Unit, with an investment of Rs 600 crore. (revised from the estimate of Rs 400 crore announced at the last General Meeting),b. Another SEZ Project with an investment of Rs 600 crore in the available land at our Unit-I in Bhuvangiri-Yadadri (erstwhile Nalgonda) District, Telangana State. The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March 2020. The Company has also taken up debottlenecking programs at Unit-I as well as Unit-II by investing an aggregate amount of Rs 300 crore -which would also create additional capacities for existing products. In addition, the company also taken up augmentation of waste treatment infrastructure at Unit-II at an estimated cost of Rs 150 crore. A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21. The balance works of the brownfield projects of DC-SEZ and DCVSEZ are also expected to be completed by second half of financial year 2020-21. As on 31 March 2020, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. Eventhough there was a nationwide lockdown restrictions due to COVID-19 pandemic since March 24, 2020, the Government has exempted manufacturing units of essential goods including drugs and pharmaceuticals, medical devices, their raw materials and intermediates from the lockdown restrictions, amongst others. The Company has been operating in compliance with the various advisories/ guidelines passed by the Government of India, State Governments and statutory institutions. The new brownfield DC and DCV SEZ Units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the FY2021. Also Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. During the year 2020-21, the company also taken up another capex program with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project. A part of the project has been completed and became operational and the rest of the capex will be completed during early part of the next financial year i.e.2021-22.

Divi's Laboratories Ltd Directors Reports

To

The Members,

Your Directors have pleasure in presenting the Annual Report of Divi's Laboratories Limited (the Company or Divi's) along with the audited financial statements for the financial year ended March 31, 2021. The consolidated performance of the Company and its subsidiaries has been referred to wherever required.

Financial Results

Financial performance of the Company for the year ended March 31, 2021 is summarized below:

(Rs in Lakhs)
Standalone Consolidated
Particulars 2020-21 2019-20 2020-21 2019-20
Revenue 6,79,861 5,31,057 6,96,940 5,39,442
Other Income 6,253 18,986 6,256 18,963
Total Revenue 6,86,114 5,50,043 7,03,196 5,58,405
Expenditure before depreciation and interest 3,97,793 3,49,513 4,10,946 3,57,225
Profit before depreciation, interest and tax (PBDIT) 2,88,321 2,00,530 2,92,250 2,01,180
Depreciation 25,465 18,595 25,559 18,624
Finance Cost 69 606 87 610
Profit before Tax (PBT) 2,62,787 1,81,329 2,66,604 1,81,946
Provision for Tax:
Current Tax 60,905 38,779 61,646 39,279
Deferred Tax 6,410 5,279 6,529 5,013
Total tax provision 67,315 44,058 68,175 44,292
Profit after Tax (PAT) 1,95,472 1,37,271 1,98,429 1,37,654
Other comprehensive Income (net of tax) 16 (521) 40 35
Total Comprehensive Income 1,95,488 1,36,750 1,98,469 1,37,689
Earnings per Share (EPS) Basic & Diluted (Rs) 73.63 51.71 74.75 51.85

Operations

Standalone

The current financial year has reflected the benefit of operations from the capex programs taken up by the Company during the last two years. The debottlenecking and backward integration programs taken up during the last two years have also become fully operational; and has reduced our dependence on key starting materials besides achieving productivity and cost efficiency. Validations have been completed for several active pharmaceutical ingredients in both the generic and Custom Synthesis products.

Ever since the outbreak of the Covid-19 pandemic, the Company has put in appropriate measures and protocols for the health and safety of its employees; besides streamlining the operations and maintaining the supply chain which enabled the Company to continue uninterrupted supply of active pharmaceutical ingredients to customers globally.

Some of the highlights of the operations for the year are:

• Total Income for the year increased by 25% to Rs 68,6114 lakhs.

• Operating profit (PBDIT) for the year amounted to Rs 2,88,321 lakhs as against an operating profit of Rs 2,00,530 lakhs last year.

• Profit before Tax (PBT) for the year has grown by 45% to Rs 2,62,787 lakhs as against a PBT of Rs 1,81,329 lakhs for the last year.

• Tax Provision for the current year amounted to Rs 67,315 lakhs as against a tax provision of Rs 44,058 lakhs for the last year.

• Profit after Tax (PAT) before other comprehensive income for the year grew by 42% to Rs 1,95,472 lakhs as against a PAT of Rs 1,37,271 lakhs last year.

• Earnings Per Share of Rs 2/- each works out to Rs 73.63 for the year as against Rs 51.71 last year.

• Out of the total revenue, 24% came from North America, 48% from Europe, 12% from Asia, 12% from India and 4% from rest of the World.

Consolidated

The Company's total consolidated income increased by 26% to Rs 7,03,196 lakhs from Rs 5,58,405 lakhs in the previous year.

The operating profit before depreciation, finance charges and tax (PBDIT) amounted to Rs 2,92,250 lakhs as against Rs 2,01,180 lakhs in the previous year. Profit after Tax, before Other Comprehensive Income, for the year accounted to Rs 1,98,429 lakhs as against Rs 1,37,654 lakhs in the previous year.

Subsidiaries

Our subsidiaries viz., M/s. Divis Laboratories (USA) Inc., in USA and M/s. Divi's Laboratories Europe AG in Switzerland are engaged in marketing/distribution of nutraceutical products and to provide a greater reach to customers within these regions.

During the year, the subsidiaries have achieved revenue of Rs 45,631 lakhs as against Rs 32,070 lakhs in the previous year, reflecting a growth of 42% of revenue at the subsidiary level.

Subsidiaries have been having consistent profits and have improved networth over the years. There has been no material change in the nature of the business of the subsidiaries.

As per Section 129(3) of the Companies Act, 2013 (the Act) read with Companies (Accounts) Rules, 2014, statement containing the salient features of the financial statement of Company's subsidiaries in form AOC-1 is annexed herewith as "Annexure I". Moreover, pursuant to provisions of Section 136(1) of the Companies Act, 2013, audited financial statements of the subsidiary companies are placed on the Company's website and can be accessed at https://www.divislabs.com/Subsidiary-Financials-2021.pdf. The Consolidated Financial Statements presented by the Company include the financial results of its subsidiary companies.

Policy for determining Material Subsidiaries, is available on the Company's corporate website and can be accessed at: https:// www.divislabs.com/MaterialSubsidiaryPolicy.pdf. Presently, the Company does not have any material subsidiary.

Consolidated financial statements

As stipulated in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and the Companies Act, 2013, the consolidated financial statements have been prepared by the Company in accordance with the relevant accounting standards. The audited consolidated financial statements together with Auditors Report thereon form part of the Annual Report.

Capital Expenditure

During the financial year 2020-21, the Company has capitalised assets of Rs 1,18,351 lakhs, and an amount of Rs 71,062 lakhs is carried forward as capital work-in-progress at the end of the year.

The new brownfield DC SEZ and DCV SEZ Units and the debottnecking / backward integration programs taken up by the Company have become fully operational during the year. Modernisation and upgradation of wastewater treatment plants at the manufacturing sites has been implemented.

During the year, we have also taken up another capex program with an estimated investment of Rs 400 crores for fast-tracking a customs synthesis project. A part of the project has been completed and became operational and the rest of the capex will be completed during early part of the next financial year.

In respect of the Kakinada site, we have received final judgement from High Court dismissing the claims of the previous landowners. We are waiting for the final go-ahead from APIIC to hand over the balance land to us. We plan to implement the Project on receiving the possession of the balance part of the land.

Material Changes and Commitments

No other material changes and commitments have occurred after the close of the year till the date of this Report, which affect the financial position of the Company. Further, there is no change in the nature of business of the Company.

Dividend

Your Directors are pleased to recommend a dividend of Rs 20/- per equity share of Rs 2/- each, i.e., 1000% for the financial year ended March 31, 2021, subject to approval of members at the ensuing Annual General Meeting.

The total dividend payout for the current year amounts to Rs 53,094 lakhs as against Rs 51,206 lakhs in the previous year. Dividend payout as a percentage of profits is 27% as compared to 37% in the previous year. As members are aware, with effect from April 01, 2020, the Government has abolished the dividend distribution tax and dividend income is now taxable at the hands of shareholders. Hence payment of dividend to members will be subject to tax deduction at source (TDS) as per statutory requirement.

The dividend recommended is in accordance with the Company's Dividend Distribution Policy. The Dividend Distribution Policy is available on the Company's website and can be accessed at https://www.divislabs.com/DividendDistributionPolicy.pdf.

Transfer to Reserves

The Directors have decided to retain the entire total comprehensive income for the current year of Rs 1,95,488 lakhs in the reserves (Retained Earnings).

Deposits

The Company has not accepted any deposits from public covered by provisions of Section 73 of the Companies Act, 2013.

Loans, Guarantees or Investments

During the year, the Company has not given any loans or guarantees covered under the provisions of Section 186 of the Companies Act, 2013.

The details of investments made by the Company are given in the notes to the financial statements.

Related Party Transactions

There are no materially significant related party transactions made by the Company with related parties which may have potential conflict of interest with the Company at large. As a matter of policy, your Company carries out transactions with related parties on an arms' length basis. Statement of these transactions is given at Note No. 38 of the Notes to financial statements.

Accordingly, particulars of contracts or arrangements with related parties referred to in Section 188(1) along with the justification for entering into such contract or arrangement in Form AOC-2 does not form part of this report.

The Policy on Materiality of Related Party Transactions and on dealing with Related Party Transactions as approved by the Board is available on the Company's website and can be accessed at https://www.divislabs.com/RPT-Policy.pdf.

Internal Financial Controls

Information in respect of internal financial controls and their adequacy is included in the Management Discussion and Analysis, which is a part of the Annual report.

Risk Management

The Company has an enterprise-wide approach to risk management, which lays emphasis on identifying and managing key operational and strategic risks. The aim is to avoid or minimise risks that pose a threat to Divi's continued existence and to make improved managerial decisions to create value. The Company has been addressing various risks impacting the Company and the policy and processes of the Company on risk management is provided in the Management Discussion and Analysis.

The Risk Management Committee constituted by the Company constantly evaluates various risks – business, customer concentration, supplier concentration, regulatory compliances, confidentiality of processes, consistency of cGMP practices, environment, employee health and safety etc., monitors risk and deploy appropriate control systems aimed at mitigating such risks to the extent possible.

Further details on the Risk Management activities including the implementation of risk management policy, key risks identified, and their mitigations are covered in Management Discussion and Analysis section, which forms part of the Annual Report.

Management Discussion and Analysis

In terms of provisions of Regulation 34(2) of SEBI Listing Regulations report on Management Discussion & Analysis for the year under review is provided in a separate section forming part of this Annual Report.

Directors' Responsibility Statement

As required under Section 134 (5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

a) the applicable accounting standards read with requirements of Schedule III to the Act have been followed in the preparation of the annual accounts for the year ended March 31, 2021 and there are no material departures from the same;

b) accounting policies selected were applied consistently and the judgements and estimates made are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at the end of the financial year and of the profit of the Company for the period;

c) proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) the annual accounts have been prepared on a going concern basis.

e) internal financial controls have been laid down and such controls are adequate and operating effectively;

f) proper systems have been laid down to ensure compliance with the provisions of all applicable laws and such systems are adequate and operating effectively.

Number of Meetings of Board of Directors

The Board meets at least four times in a year at quarterly intervals and more frequently if deemed necessary, to transact its business. During the financial year, the Board has met four times, i.e. on June 06, 2020, August 08, 2020, November 07, 2020 and February 06, 2021.

Directors and Key Managerial Personnel

As per the provisions of the Companies Act, 2013 and the Articles of Association of the Company, Dr. Kiran S. Divi and Ms. Nilima Prasad Divi, Directors of the Company, will retire by rotation at the ensuing Annual General Meeting and being eligible, the Directors offer themselves for re-appointment. The Board of Directors, on recommendation of Compensation, Nomination and Remuneration Committee, has recommended their reappointment.

Declaration by Independent Directors

The Company has obtained declaration from all Independent Directors of the Company under Section 149(7) of the Companies (the Act), 2013 confirming that they meet the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 and Regulation 25 of SEBI Listing Regulations. There has been no change in the circumstances affecting their status as Independent Directors of the Company.

Performance Evaluation

The Board of Directors carried out an annual evaluation of its own performance, of the Committees of the Board and of the individual directors including Independent Directors, pursuant to the provisions of the Companies Act, 2013 and SEBI Listing Regulations.

Performance evaluation was carried out on the basis of criteria evolved, as provided by the Guidance Note on Board Evaluation issued by Securities and Exchange Board of India, seeking inputs from the Directors individually and the committees through a structured questionnaire which provides a valuable feedback for contribution to the Board, improving Board effectiveness, maximising strengths and highlighting areas for further improvement etc.,

In a separate meeting of the Independent Directors, performance of the Chairperson, non-independent directors and the Board as a whole was evaluated taking into account the views of the non-independent directors and the same was discussed in the Board Meeting. Performance evaluation of Independent Directors is done by the entire Board of Directors (excluding the Directors being evaluated).

Policy on Directors' Appointment and Remuneration

The Policy on appointment and remuneration of Directors, Key Managerial Persons and Senior Management including criteria for determining qualifications, positive attributes and director's independence as required under Section 178(3) of the Companies Act, 2013 and Regulation 19 read with Schedule II Part D of SEBI Listing Regulations has been formulated by the Company:

• To identify persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down.

• To ensure a transparent board nomination process with the diversity of thought, experience, knowledge, perspective and gender in the Board.

• To determine remuneration based on the Company's size and financial position and trends and practices on remuneration prevailing in peer companies, in the Pharma industry besides qualifications, skills, capabilities etc.,

• To carry out evaluation of the performance of Directors, as well as Key Managerial and Senior Management Personnel.

• To provide them rewards linked directly to their effort, performance, dedication and achievement relating to the Company's operations.

• To retain, motivate and promote talent and to ensure long term sustainability of talented managerial persons and create competitive advantage.

Policy on Nomination and Remuneration of Directors, Key / Senior Managerial Personnel may be accessed on the Company's website at: https://www.divislabs.com/ NominationRemunerationPolicy.pdf.

Remuneration Details of Directors and KMP

Particulars required to be furnished under Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended are given in "Annexure – II" and forms part of this Report.

The non-executive directors of the Company had no pecuniary relationship or transactions with the Company, other than sitting fees, annual remuneration and reimbursement of expenses, if any.

Particulars of Employees

Particulars of employees required to be furnished under Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended are given in "Annexure – III" and forms part of this Report.

Corporate Social Responsibility

The Board of Directors has constituted Corporate Social Responsibility Committee (CSR Committee) consisting of members viz. Mr. R. Ranga Rao (Chairman), Dr. Murali K. Divi, Mr. Madhusudana Rao Divi and Dr. Ramesh B.V. Nimmagadda.

Corporate Social Responsibility Policy (CSR Policy) indicating the activities to be undertaken by the Company was adopted by the Board on the recommendation of the CSR Committee.

Report on Corporate Social Responsibility as per Rule 8 of Companies (Corporate Social Responsibility Policy) Rules, 2014 is prepared and the same is enclosed as "Annexure – IV" to this Report.

Business Responsibility Report

Pursuant to the SEBI Listing Regulations, Business Responsibility Report (BRR) describing the initiatives taken by the Company is enclosed as part of this Report.

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings & Outgo

Particulars required under Section 134 (3) (m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is given in the "Annexure – V" to this report.

Corporate Governance Report

The report on Corporate Governance as per Regulation 34(3) read with Schedule V of the SEBI Listing Regulations is included as a part of this Annual Report. The requisite certificate from Mr. V. Bhaskara Rao, Practicing Company Secretary confirming the compliance with the conditions of Corporate Governance is attached to the report on Corporate Governance.

Audit Committee

The details pertaining to the role, objective and composition of the Audit Committee are included in the Corporate Governance Report which is part of the Annual Report for the year.

Vigil Mechanism

The Company has established a vigil mechanism and formulated a Whistle Blower Policy to provide mechanism for directors and employees of the Company to report their concerns about any unethical behavior, actual or suspected fraud or violation of the Company's code of conduct or ethics policy. The Policy provides that the Company investigates such incidents, when reported, in an impartial manner and takes appropriate action to ensure that requisite standards of professional and ethical conduct are always upheld. This mechanism also provides for adequate safeguards against victimization of director(s)/ employee(s) who avail the mechanism and also provide for direct access to the Chairman of the Audit Committee in exceptional cases. The Whistle Blower Policy may be accessed on the Company's website at: https://www.divislabs.com/WhistleBlowerPolicy.pdf.

Audit Reports

• Report of the Statutory Auditors on the financial statements for the year does not contain any qualification, reservation or adverse remark or disclaimer; or reporting of any offence or fraud.

• The Secretarial Audit Report does not contain any qualification, reservation or adverse remark or disclaimer.

Statutory Auditors

At the Annual General Meeting held on September 25, 2017, M/s Price Waterhouse Chartered Accountants LLP (Firm Registration No. 012754N/ N500016) were appointed as Statutory Auditors of the Company to hold office for five consecutive years till the conclusion of the 32nd Annual General Meeting of the Company in the calendar year 2022, subject to ratification by the members at each Annual General Meeting.

In terms of first proviso to Section 139 of the Companies Act, 2013, the appointment of the auditors shall be placed for ratification at every Annual General Meeting. However, Companies (Amendment) Act, 2017 omitted the first proviso to Section 139 of Companies Act, 2013 that requires ratification of appointment of auditor at every annual general meeting.

Accordingly, M/s. Price Waterhouse Chartered Accountants LLP will continue as the Statutory Auditors of the Company till conclusion of 32nd Annual General Meeting of the Company.

Secretarial Audit

Pursuant to provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors of the Company has appointed Mr. V. Bhaskara Rao, Practicing Company Secretary (PCS Registration No. 4182) as the Secretarial Auditor of the Company to conduct the Secretarial audit for the financial year 2020-21. The Secretarial Audit report for the financial year 2020-21 is annexed herewith as "Annexure VI".

Cost Audit

Pursuant to the Section 148 of the Act and Rule 3 of the Companies (Cost Records and Audit) Rules, 2014 as amended, the Company maintains cost records in its books of account. As per Rule 4 of the said rules, the requirement for cost audit is not applicable to a company which is covered under Rule 3, and whose revenue from exports, in foreign exchange, exceeds seventy five per cent of its total revenue or which is operating from a special economic zone. However, the Company has voluntarily opted for audit of cost records and appointed M/s. E.V.S & Associates, Cost Accountants as Cost Auditors.

Annual Return

In terms of Section 92(3) of the Companies Act, 2013 and Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return of the Company as on March 31, 2021 is available on the Company's website and can be accessed at https://www.divislabs.com/annual-return/2020-21.pdf

Other Disclosures

• Information on Unclaimed Dividend and transfer to IEPF is provided in the Corporate Governance Report.

• No Company has become or ceased to be its subsidiary, joint venture or associate Company during the year.

• No significant and material orders were passed by the regulators or courts or tribunals impacting the going concern status and Company's operations in future.

• The Company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and rules made thereunder and during the year under review, there were no complaints received or pending.

• The information with respect to Compensation, Nomination and Remuneration Committee, Stakeholders Relationship Committee, Risk management Committee are disclosed in the Corporate Governance Report forming part of the Annual Report.

• The Company has followed the applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to ‘Meetings of the Board of Directors' and ‘General Meetings' respectively.

Acknowledgements

Your Directors take this opportunity to thank the customers, shareholders, suppliers, bankers, business associates, financial institutions and Central and State Governments for their consistent support and encouragement to the Company.

We are sure you will join our Directors in conveying our sincere appreciation to employees at all levels of the Company and its subsidiaries, for their hard work, dedication and commitment, in particular during this unprecedented year, thereby ensuring uninterrupted supply of life saving medicines across the globe.

For and on behalf of the Board
Dr. Ramesh B.V. Nimmagadda Dr. Murali K. Divi
Chairman Managing Director
(DIN: 07854042) (DIN: 00005040)
Date: May 29, 2021 Place: Chennai Place: Hyderabad

   

Divi's Laboratories Ltd Company Background

Ramesh B V NimmagaddaMurali K Divi
Incorporation Year1990
Registered Office1-72-23(P)/DIVIS/303 Divi Towe,Cyber Hills Gachibowli
Hyderabad,Telangana-500032
Telephone91-40-23786300/23786352/400,Managing Director
Fax91-40-23786460
Company SecretarySatish Choudhury
AuditorPrice Waterhouse Chartered Accountants LLP
Face Value2
Market Lot1
ListingBSE,MSEI ,NSE,
RegistrarKFin Techologies Pvt Ltd
Karvy Selenium Tow-B,31&32 Financial Dist,Nanakramguda ,Hyderabad-500032

Divi's Laboratories Ltd Company Management

Director NameDirector DesignationYear
Murali K Divi Chairman & Managing Director 2021
N V Ramana Executive Director 2021
Madhusudana Rao Divi Director (Projects) 2021
Kiran S Divi Whole Time Director & CEO 2021
G Suresh Kumar Independent Director 2021
Ranga Rao Ravipati Independent Director 2021
K V K Seshavataram Independent Director 2021
Ramesh B V Nimmagadda Chairman (Non-Executive) 2021
Nilima Motaparti Whole Time Director -Commercia 2021
S Ganapaty Independent Director 2021
Sunaina Singh Independent Director 2021
Kosaraju Veerayya Chowdary Independent Director 2021
Satish Choudhury Company Secretary 2021

Divi's Laboratories Ltd Listing Information

Listing Information
NIFTY
BSE_500
BSE_HC
BSE_100
BSE_200
BSEDOLLEX
CNX500
CNXPHARMA
CNX100
CNX200
NFTALPHA50
BSECARBONE
NI15
BSEALLCAP
BSELARGECA
BSEMANUFAC
SENSEX50
ESG100
LMI250
BSEDSI
BSELVI
BSEMOI
BSEQUI
BSE100LTMC
NFTYLM250
NFTY200Q30
NFTYALV30
NFTY200M30
NFTYHEALTH
NF500M5025

Divi's Laboratories Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Sale of Products NA 0005198.31
Export incentives NA 00086.48
Sale of Scrap NA 00016.77
Sale of Services NA 0009.01
API Intermediates MT 0000
API Intermediates Traded NA 0000
Bulk Drugs & Interm.-Others MT 0000
Traded Goods NA 0000
Excise Duty NA 0000
Other Operating Revenue NA 0000

Contact us Contact us